PMID- 23065263
OWN - NLM
STAT- MEDLINE
DCOM- 20130404
LR  - 20211021
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 39
IP  - 12
DP  - 2012 Dec
TI  - DNA methylation and expression profiles of the brain-derived neurotrophic factor 
      (BDNF) and dopamine transporter (DAT1) genes in patients with schizophrenia.
PG  - 10889-93
LID - 10.1007/s11033-012-1986-0 [doi]
AB  - Methylation and expression profile of CpG islands were examined in the promoters 
      of the brain-derived neurotrophic factor (BDNF) and dopamine transporter (DAT1) 
      genes. These are well known to be involved in the pathophysiology of psychiatric 
      disorders such as schizophrenia. Genomic DNA was extracted from peripheral blood 
      of 80 patients with schizophrenia and 71 healthy controls. Methylation pattern 
      was studied by Methylation-Specific PCR. RNA expression analysis was done on 
      extracted RNA from blood samples from patients suffering from schizophrenia (n = 
      17) and healthy controls (n = 17). Frequency of the BDNF gene methylation was 
      highlighted as a statistically significant relationship between cases and 
      controls regarding decreased risk of disease in comparison to unmethylated 
      patterns (OR = 0.24; 95 % CI = 1.11-0.50; P = 0.00007). For the DAT1 gene, this 
      relationship was insignificant in 61 cases (76.25 %) and 52 controls (73.23 %) 
      (OR = 1.17; 95 % CI = 0.53-2.61). Estimates of relative gene expression revealed 
      a statistically significant association of the BDNF gene between schizophrenic 
      patients and healthy controls (Mean +/- SD: 13.3920 +/- 15.19 and 0.437 +/- 0.328, P = 
      0.0001) respectively; however, it was not significant for the DAT1 gene. This 
      first hand evidence, regarding BDNF and DAT1 gene methylation and their 
      expression profile with risk of schizophrenia, indicated a significant function 
      for the BDNF gene in the development of schizophrenia. However, further 
      populations with large sample sizes need to be studied to verify the exact role 
      of BDNF in mental disorders such as schizophrenia.
FAU - Kordi-Tamandani, Dor Mohammad
AU  - Kordi-Tamandani DM
AD  - Department of Biology, University of Sistan and Baluchestan, P.O. Box 98155-987, 
      Zahedan, Iran. dor_kordi@yahoo.com
FAU - Sahranavard, Roya
AU  - Sahranavard R
FAU - Torkamanzehi, Adam
AU  - Torkamanzehi A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20121014
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (SLC6A3 protein, human)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Brain-Derived Neurotrophic Factor/*genetics/metabolism
MH  - Case-Control Studies
MH  - DNA Methylation/*genetics
MH  - Dopamine Plasma Membrane Transport Proteins/*genetics/metabolism
MH  - *Gene Expression Profiling
MH  - *Gene Expression Regulation
MH  - Humans
MH  - Middle Aged
MH  - Schizophrenia/*genetics
MH  - Young Adult
EDAT- 2012/10/16 06:00
MHDA- 2013/04/05 06:00
CRDT- 2012/10/16 06:00
PHST- 2012/02/27 00:00 [received]
PHST- 2012/10/01 00:00 [accepted]
PHST- 2012/10/16 06:00 [entrez]
PHST- 2012/10/16 06:00 [pubmed]
PHST- 2013/04/05 06:00 [medline]
AID - 10.1007/s11033-012-1986-0 [doi]
PST - ppublish
SO  - Mol Biol Rep. 2012 Dec;39(12):10889-93. doi: 10.1007/s11033-012-1986-0. Epub 2012 
      Oct 14.